Company News

Peter Gaccione Joins Myocardial Solutions as President to Lead Commercialization of Cardio-Oncology Solution

Myocardial Solutions, Inc. announced today that it has hired Peter Gaccione as President effective April 13, 2020.

Blurred light stretches along windy, mountainous road

May 28, 2020

Myocardial Solutions Named Top 50 Most Innovative Companies to Watch in 2020

April 25, 2020

New ESC Webinar Highlights MyoStrain® Cardio-Oncology Solution for the Early Detection & Management of Cancer Patient Cardiotoxicity

March 31, 2020

Six Abstracts Featuring MyoStrain Published at American College of Cardiology 2020 Scientific Sessions

handheld digital heart model floating in hand

February 18, 2020

Sixteen MyoStrain Abstracts, Posters & Podium Presentations Presented at SCMR 2020

chemotherapy treatment dripping from syringe

October 11, 2019

New Abstract: Utilizing MyoStrain to Detect Cardiotoxic Effects of Carfilzomib

digital human model displaying internal organs

September 5, 2019

Eight New MyoStrain Posters and Presentations Presented at ESC Congress in Paris 2019

young medical professionals excited for learning

August 21, 2019

New Publication Evaluates the Effects of Experience & Training on MyoStrain Reproducibility

medical professionals conversing in hospital storage room office

June 19, 2019

MyoStrain's Economic Benefits in the Diagnosis and Management of Heart Failure Detailed in New Health Economics Review

June 13, 2019

New PROACT Study to Evaluate MyoStrain in the Detection & Management of Cardiotoxicity in Cancer Patients

Contact Us

We're here to answer your questions. Learn how MyoStrain can help transform your cardiac practice.

Reach Out

Peter Gaccione Joins Myocardial Solutions as President to Lead Commercialization of Cardio-Oncology Solution

Myocardial Solutions Named Top 50 Most Innovative Companies to Watch in 2020

New ESC Webinar Highlights MyoStrain® Cardio-Oncology Solution for the Early Detection & Management of Cancer Patient Cardiotoxicity

Six Abstracts Featuring MyoStrain Published at American College of Cardiology 2020 Scientific Sessions

Sixteen MyoStrain Abstracts, Posters & Podium Presentations Presented at SCMR 2020

New Abstract: Utilizing MyoStrain to Detect Cardiotoxic Effects of Carfilzomib

Eight New MyoStrain Posters and Presentations Presented at ESC Congress in Paris 2019

New Publication Evaluates the Effects of Experience & Training on MyoStrain Reproducibility

MyoStrain's Economic Benefits in the Diagnosis and Management of Heart Failure Detailed in New Health Economics Review

New PROACT Study to Evaluate MyoStrain in the Detection & Management of Cardiotoxicity in Cancer Patients

MyoStrain on Social Media

Contact Us

Quick Links

Sign Up

Myocardial Solutions Introduces New MyoStrain® Webinar Series

Newsletter

Company News

Peter Gaccione Joins Myocardial Solutions as President to Lead Commercialization of Cardio-Oncology Solution

Myocardial Solutions Named Top 50 Most Innovative Companies to Watch in 2020

New ESC Webinar Highlights MyoStrain® Cardio-Oncology Solution for the Early Detection & Management of Cancer Patient Cardiotoxicity

Six Abstracts Featuring MyoStrain Published at American College of Cardiology 2020 Scientific Sessions

Sixteen MyoStrain Abstracts, Posters & Podium Presentations Presented at SCMR 2020

New Abstract: Utilizing MyoStrain to Detect Cardiotoxic Effects of Carfilzomib

Eight New MyoStrain Posters and Presentations Presented at ESC Congress in Paris 2019

New Publication Evaluates the Effects of Experience & Training on MyoStrain Reproducibility

MyoStrain's Economic Benefits in the Diagnosis and Management of Heart Failure Detailed in New Health Economics Review

New PROACT Study to Evaluate MyoStrain in the Detection & Management of Cardiotoxicity in Cancer Patients

MyoStrain on Social Media

Contact Us

Quick Links

Sign Up